VERdoxo-M
Description_Effects
VERdoxo-M is a combination medication that contains Doxofylline and Montelukast, designed to manage and prevent respiratory conditions like asthma, chronic bronchitis, and allergic rhinitis. The synergistic action of both components offers comprehensive relief from airway inflammation and bronchoconstriction. Doxofylline is a bronchodilator that works by relaxing the smooth muscles of the airways, allowing them to widen and improve airflow into the lungs. It belongs to the xanthine class of drugs but has a safer profile than traditional theophylline, causing fewer cardiovascular and central nervous system side effects. It helps ease symptoms like shortness of breath, chest tightness, and wheezing, making breathing more comfortable for patients. Montelukast is a leukotriene receptor antagonist. It works by blocking leukotrienes—chemical messengers involved in the inflammatory process in asthma and allergies. By inhibiting leukotriene activity, Montelukast reduces airway inflammation, swelling, and mucus production, helping prevent asthma attacks and manage symptoms of allergic rhinitis like sneezing, nasal congestion, and runny nose. VERdoxo-M is usually taken once daily, preferably in the evening. It is important to use the medication regularly for best results. While generally well-tolerated, some patients may experience mild side effects like headache, nausea, abdominal discomfort, or drowsiness. Always use under medical supervision.
